Physician profile
Alison Mitchell Rumball
NPI 1386133502
$1,611.25
in general payments reported to CMS, 2019-2025
29 companies · $15.57 in 2025
The $15.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.87 · 2022: $608 · 2023: $736 · 2024: $198 · 2025: $15.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $314.61 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $204.01 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $172.17 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.46 | 2022-2023 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $94.03 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $73.07 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.05 | 2022-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $62.16 | 2022 | |
| Currax Pharmaceuticals LLC | $60.65 | 2022-2023 | Contrave, Onzetra Xsail |
| Xeris Pharmaceuticals, INC. | $44.95 | 2022-2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $43.12 | 2022-2023 | Quviviq |
| Impel Pharmaceuticals INC. | $36.14 | 2022-2023 | Trudhesa |
| Esperion Therapeutics, INC. | $35.55 | 2022-2023 | Nexletol |
| Amgen INC. | $34.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.31 | 2023 | Breztri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $25.34 | 2024 | Zio Xt Patch, Zio Monitor |
| Lundbeck LLC | $21.88 | 2023 | Vyepti |
| Axsome Therapeutics, INC. | $20.93 | 2023 | Sunosi |
| Novartis Pharmaceuticals Corporation | $20.42 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $20.16 | 2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $17.77 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.18 | 2022 | |
| Glaxosmithkline, LLC. | $15.26 | 2022 | |
| Exact Sciences Corporation | $15.08 | 2023 | Cologuard Collection Kit |
| Organon LLC | $15.04 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $14.14 | 2021 | |
| Hikma Pharmaceuticals USA | $14.02 | 2023 | Ryaltris |
| Nestle Healthcare Nutrition INC. | $13.79 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Rumball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.